This unexpected oncogenic function of PUMA identifies it as a promising therapeutic target and suggests a synergistic effect when combined with FASN inhibitors to inhibit tumor growth in ccRCC. This evidence concerns the gene BBC3 and nonpapillary renal cell carcinoma.